Department of Quality and Safety, Brigham and Women's Hospital, MA, Boston, USA.
Department of Quality and Safety, NYC Health + Hospitals, New York, NY, USA.
J Gen Intern Med. 2023 Aug;38(10):2326-2332. doi: 10.1007/s11606-023-08201-8. Epub 2023 May 2.
25-Hydroxyvitamin D testing is increasing despite national guidelines and Choosing Wisely recommendations against routine screening. Overuse can lead to misdiagnosis and unnecessary downstream testing and treatment. Repeat testing within 3 months is a unique area of overuse.
To reduce 25-hydroxyvitamin D testing in a large safety net system comprising 11 hospitals and 70 ambulatory centers.
This was a quality improvement initiative with a quasi-experimental interrupted time series design with segmented regression.
All patients in the inpatient and outpatient settings with at least one order for 25-hydroxyvitamin D were included in the analysis.
An electronic health record clinical decision support tool was designed for inpatient and outpatient orders and involved two components: a mandatory prompt requiring appropriate indications and a best practice advisory (BPA) focused on repeat testing within 3 months.
The pre-intervention period (6/17/2020-6/13/2021) was compared to the post-intervention period (6/14/2021-8/28/2022) for total 25-hydroxyvitamin D testing, as well as 3-month repeat testing. Hospital and clinic variation in testing was assessed. Additionally, best practice advisory action rates were analyzed, separated by clinician type and specialty.
There were 44% and 46% reductions in inpatient and outpatient orders, respectively (p < 0.001). Inpatient and outpatient 3-month repeat testing decreased by 61% and 48%, respectively (p < 0.001). The best practice advisory true accept rate was 13%.
This initiative successfully reduced 25-hydroxyvitamin D testing through the use of mandatory appropriate indications and a best practice advisory focusing on a unique area of overuse: the repeat testing within a 3-month interval. There was wide variation among hospitals and clinics and variation among clinician types and specialties regarding actions to the best practice advisory.
尽管有国家指南和明智选择建议反对常规筛查,但 25-羟维生素 D 检测的应用仍在增加。过度使用可能导致误诊和不必要的下游检测和治疗。在 3 个月内重复检测是过度使用的一个独特领域。
在一个由 11 家医院和 70 个门诊中心组成的大型安全网系统中减少 25-羟维生素 D 的检测。
这是一项质量改进计划,采用具有分段回归的准实验中断时间序列设计。
所有在住院和门诊环境中至少有一次 25-羟维生素 D 检测订单的患者都被纳入分析。
为住院和门诊订单设计了电子健康记录临床决策支持工具,该工具包括两个组件:一个强制性提示,要求提供适当的适应症;一个最佳实践建议(BPA),重点关注 3 个月内的重复检测。
将干预前时期(2020 年 6 月 17 日至 2021 年 6 月 13 日)与干预后时期(2021 年 6 月 14 日至 2022 年 8 月 28 日)进行比较,比较总 25-羟维生素 D 检测以及 3 个月的重复检测。评估了医院和诊所检测的变化。此外,还分析了最佳实践建议的行动率,按临床医生类型和专业进行了区分。
住院和门诊订单分别减少了 44%和 46%(p<0.001)。住院和门诊 3 个月的重复检测分别减少了 61%和 48%(p<0.001)。最佳实践建议的真实接受率为 13%。
通过使用强制性的适当适应症和一个专注于过度使用的独特领域(即 3 个月内的重复检测)的最佳实践建议,该倡议成功地减少了 25-羟维生素 D 的检测。医院和诊所之间以及临床医生类型和专业之间在最佳实践建议的行动方面存在很大差异。